BMI View: The Argentinean pharmaceutical market will continue to experience downward pressure owing
to a contraction in consumption indices in the near term. In the long term, however, market growth
fundamentals will remain robust, creating commercial and investment o ..."
BMI View: In the near term, the substandard regulatory and market access environment will continue to
tarnish Argentina's appeal to drugmakers. However, in the long term, Argentina stands among the most
promising pharmaceutical markets in Latin America in terms of gro ..."
BMI View: Over the next five years, Argentina's pharmaceutical and healthcare sector growth trends are
expected to substantially benefit from the improving business environment, including the liberalisation of
the country's external accounts. Moreover, Argentina's geo ..."
BMI View: Robust pharmaceutical and healthcare market growth in Argentina will lead to improved
opportunities for drugmakers over the next 10 years. Despite the government's increased focus on domestic
pharmaceutical production, Argentina will retain its negative phar ..."
BMI View: The improvement in Argentina's business environment that is expected take place with the next
government administration will contribute to increased market attractiveness to pharmaceuticals and
healthcare investors. Moreover, a recent agreement aimed at impr ..."
BMI View: Argentina's pharmaceuticals and healthcare sector is expected to experience improved growth
rates through the next decade, standing slightly behind growth patterns in the other large markets in Latin
America. Combined with expected improvements in the Argent ..."
BMI View: Despite economic activity forecast to continue to decline over the medium-term, Argentina's
gradual transition towards more pragmatic and market-friendly economic policies will likely benefit key
economic sectors in the long-term, including the pharmaceutical industry ..."
BMI View: We expect increasing competitive pressure in the Argentine pharmaceutical sector as South-
South relations continue to develop. This is illustrated by the Argentine government recent authorization for
Indian pharmaceutical firms to export finished formulations to Arge ..."
BMI View: The Argentine economy is still reeling from the January 2014 currency devaluation. Soaring
inflation and stringent drug pricing controls will continue to discourage investment and erode the growth of
the country's pharmaceutical market. More foreign pharmace ..."
BMI View: Argentina's unpredictable and highly interventionist style of government practices will not be
able to amend the country's economic concerns or resolve issues in the pharmaceutical industry. The local
pharmaceutical market and healthcare system will continue ..."